Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanomaRichard Kefford, Adil Daud, Patrick Chun et al.|Unknown|2014Cited by 0